Glaxo drinks deep with $9bn bond as US brims with cash
It was another $30bn week in the all-guns-blazing US investment grade bond market, but the clear star of the show was the $9bn four tranche offering for UK pharmaceutical firm GlaxoSmithKline, which pulled a staggering $17.8bn of orders.
 |
Launched to fund a share buyback programme, the deal broke several US dollar high grade records.It was the largest corporate Yankee issue since British Telecom in 2000; the biggest corporate bond since WorldCom in 2001; and the largest ever corporate issue outside the telecom ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Or sign up for a trial to gain full access to the entire site for a limited period.
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.
